Antibody Drug Evaluation & Testing
Cell-based assays read out functional activity quickly and animal models confirm in vivo tumour control — the early evidence a candidate needs to advance.
Accurate, reliable in vitro efficacy evaluation is the foundation on which candidates are screened and optimised. SanjingBio's systematic platform reads functional activity at the cell level quickly and precisely, keyed to each target's mechanism, giving the early evidence that later development depends on.
In vivo efficacy screening is the pivotal preclinical step for antibodies, ADCs and other biologics, and it determines how truthfully a candidate's therapeutic potential is predicted. We assess tumour control and preliminary safety in standardised tumour-bearing models, providing the core evidence for advancing a candidate.
Cell and animal disease models are established to assess a candidate's biological activity, pharmacokinetics and therapeutic effect in full.
Enquire now →
Bespoke efficacy models are built and validated strictly from the target biology, keeping the basis of evaluation sound.
Validated standard operating procedures are followed throughout, with disciplined process and quality control keeping data accurate and reproducible.
Free of fixed-model constraints, assays are combined around your target's mechanism to give a genuinely individual evaluation plan.
We work as an extension of your team, collaborating closely from study design through data analysis so every step serves your goal.
A ready library of animal models covers the major tumour types — stable and highly reproducible, so studies start quickly and a full in vivo efficacy assessment from tumour inoculation to end of dosing can finish in as little as 4 weeks.
An extensive stock of reference antibodies and validated tumour cell lines keeps study design sound, results reliable and within-group variance under control.
An experienced in vivo efficacy team runs the study to standard procedures, closely observing and recording tumour volume, body weight and other measures to keep data truthful and accurate.
Multi-dimensional analysis covering tumour growth curves, tumour growth inhibition (TGI) and survival, delivered as a professional report that presents the candidate's in vivo efficacy clearly.
Five stages. In vitro evaluation reads functional activity at the cell level from the target's mechanism; in vivo screening assesses tumour control and preliminary safety in standardised models. The two can be commissioned separately or run in sequence.
Bespoke models are built from the target biology, or drawn from the ready model library
Assays are combined flexibly, with reference antibodies and validated tumour cell lines assigned
Binding, pathway modulation, internalisation, killing and immune cell function assays
Dosing proceeds to plan while tumour dimensions, body weight and survival are recorded regularly
Tumour volume and TGI calculated, growth curves plotted and statistics run, delivered as a professional report
An in vivo study can run from tumour inoculation to end of dosing in as little as 4 weeks. In vitro assays span binding and competition, pathway modulation, antibody internalisation and degradation, direct killing and proliferation inhibition, immune cell function (ADCC/CDC, T cell activation, cytokine release), plus enzyme inhibition, chemotaxis and other functional readouts.
A ready library of animal models covers the major tumour types — stable, reproducible and quick to start — backed by an extensive stock of reference antibodies and validated tumour cell lines that keep within-group variance under control. CDX and other mainstream models are available, with BALB/c nude, NPG and other immunodeficient strains as required.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
